- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04965233
Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes
September 13, 2021 updated by: Studies&Me
Atopic eczema is a common skin disorder affecting at least 2-3% of the western population.
Atopic eczema cannot be cured and therefore treatment aims to alleviate the symptoms of the disease.
Today, many different medical treatments are available: from mild hormone creams to harsh systemic treatments.
The treatment chosen depends in part on the severity of the eczema and on the treatment response of the individual.
This practice may mean that some people with eczema undergo unnecessary treatment courses with associated side effects.
We know today that eczema has a hereditary component, and different areas have been identified in the hereditary material that appear to play a role.
Although it is thought that variations in specific areas of the inheritance material may influence how eczema is expressed in the individual, the significance of these variations is far from clarified.
The investigators want to increase the knowledge about atopic eczema, about the disease and how in the future we can organize the treatment of eczema based on knowledge of our genetic material.
In this study, the investigators want to elucidate whether there is a correlation between specific variations in the genetic material and how the eczema is clinically expressed.
In addition, the investigators want to assess whether reports with specific information about the individual's genetic material in relation to his or her lifestyle can help retain participants in research projects.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Copenhagen, Denmark, 1113
- Studies&Me
-
-
-
-
California
-
Redwood City, California, United States, 94063
- 450 Broadway F4
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Recruitment is performed through the Studies&Me platform (https://studiesandme.com/), which is recruiting and screening people with AD, who are generally interested in participating in a study related to their disease.
Participants will also be recruited through clinics and hospitals.
Description
Inclusion Criteria:
- Informed consent has been signed
- 18 years or older
- Resident in the USA or Denmark
- AD meeting the UK Diagnostic Criteria for Atopic Dermatitis
- At least one visible AD lesion at the time of recruitment (as confirmed remotely through photo upload in screening)
- Smartphone user with daily access to internet (WIFI or 3G/4G)
- Willing to donate a DNA sample
- Confirmed intention to comply with study protocol procedures
Exclusion Criteria:
- Female subjects that are pregnant (or plan to become so during the study period) or lactating
- Active dermatological condition that may confound the diagnosis of AD and/or the assessment of disease activity
- Unable to speak or understand English or Danish
- Overlap with participation in interventional trials
- No visible AD at time of screening
- Any other reasons that in the investigator's opinion could:
- Impede a subject's ability to complete the study period
- Influence the objectivity or quality of the findings of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants recruited in Denmark
Participants recruited in Denmark will consist of 63 healthy individuals and 187 individuals with atopic dermatitis
|
Reports containing general information on eczema
|
Participant recruited in the United States of America
Participants recruited in the US will consist of 125 healthy individuals, 3000 individuals with atopic dermatitis
|
The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in AD phenotype measured on a weekly basis for 12 weeks using the SCORing Atopic Dermatitis (SCORAD) evaluated remotely through photos by investigator assessment.
Time Frame: 12 weeks
|
SCORAD measures the severity of eczema on a scale from 0-103.
|
12 weeks
|
Change in AD phenotype measured on a weekly basis for 12 weeks using the Three Item Severity Score (TIS) evaluated remotely through photos by investigator assessment.
Time Frame: 12 weeks
|
TIS measures the severity of erythema, oedema/papulation and excoriation on a scale from 0-9.
|
12 weeks
|
Change in AD phenotype measured on a weekly basis for 12 weeks using the Eczema Area and Severity Index (EASI) evaluated remotely through photos by investigator assessment.
Time Frame: 12 weeks
|
EASI measures the severity and body surface area of eczema on a scale from 0-72.
|
12 weeks
|
Change in AD phenotype measured on a weekly basis for 12 weeks using the The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD)) evaluated remotely through photos by investigator assessment.
Time Frame: 12 weeks
|
vIGA-AD measures the severity of eczema on a scale from 0-4.
|
12 weeks
|
Change in AD phenotype measured on a weekly basis for 12 weeks using the Patient Oriented Eczema Measurement (POEM) questionnaire.
Time Frame: 12 weeks
|
POEM measures the severity of eczema as experienced by the patient on a scale from 0-28.
|
12 weeks
|
Change in AD phenotype measured on a weekly basis for 12 weeks using the Skindex-mini questionnaire.
Time Frame: 12 weeks
|
Skindex-mini measures the symptomatic, emotional and functional aspects of an individual's skin disorder on a scale from 0-18.
|
12 weeks
|
Change in AD phenotype measured on a weekly basis for 12 weeks using the Patient's Global Impression of Severity Numerical Rating System (PGIS-NRS) questionnaire.
Time Frame: 12 weeks
|
PGIS-NRS measures the impression of severity of an individual's skin disorder on a scale from 0-10.
|
12 weeks
|
Change in AD phenotype measured on a weekly basis for 12 weeks using the Eczema-related sleep quality NRS questionnaire.
Time Frame: 12 weeks
|
Eczema-related sleep quality NRS measures the sleep quality, itch and dryness on a scale from 0-10.
|
12 weeks
|
Change in AD phenotype measured by patient-perceived flare ups on a weekly basis for 12 weeks.
Time Frame: 12 weeks
|
Number of days on a weekly basis with flare ups.
|
12 weeks
|
Change in AD phenotype measured by the disease extent method on a weekly basis for 12 weeks.
Time Frame: 12 weeks
|
Palm method to measure AD affected body surface area (0-100%).
|
12 weeks
|
Change in AD phenotype measured by the Eczema Area and Severity Index (EASI) on a weekly basis for 12 weeks.
Time Frame: 12 weeks
|
EASI measures the severity and body surface area of eczema on a scale from 0-72.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Personalized DNA lifestyle reports/information reports as an engagement tool in clinical trials
Time Frame: 12 weeks
|
Number of completers receiving DNA lifestyle reports/information reports at different time points will be compared to evaluate effect on retention.
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between environmental factors and AD flare ups
Time Frame: 12 weeks
|
Passive data on geographical localisation, daily activity level and an approximation for length of sleep
|
12 weeks
|
Number of days on a weekly cycle of patient-use of medication/treatment
Time Frame: 12 weeks
|
Number of days on a weekly cycle of patient-use of medication/treatment
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Justin M Ko, MD, MBA, Study Principal Investigator
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2020
Primary Completion (Anticipated)
December 31, 2021
Study Completion (Anticipated)
December 31, 2021
Study Registration Dates
First Submitted
June 30, 2021
First Submitted That Met QC Criteria
July 15, 2021
First Posted (Actual)
July 16, 2021
Study Record Updates
Last Update Posted (Actual)
September 20, 2021
Last Update Submitted That Met QC Criteria
September 13, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-19020696
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eczema
-
Technical University of MunichCelgene CorporationCompletedEczema | Nummular Eczema | Dermatitis Eczema | Nummular DermatitisGermany
-
Odense University HospitalCompletedVesicular Palmoplantar Eczema | PompholyxDenmark
-
Gary GoldenbergCompletedHand Eczema | Foot EczemaUnited States
-
Zealand University HospitalUniversity of Copenhagen; Danish Working Environment FundCompleted
-
SalvatCompleted
-
University Hospitals Coventry and Warwickshire...University of WarwickNot yet recruitingCancer | Skin Cancer | Dry Skin; Eczema | Medical Device Site EczemaUnited Kingdom
-
Incyte CorporationActive, not recruitingHand EczemaUnited States, Poland, Canada, Germany
-
Incyte CorporationWithdrawnHand EczemaUnited States, Germany, Spain, Czechia, Canada, Poland
-
University Hospital Bispebjerg and FrederiksbergStatens Serum InstitutRecruiting
Clinical Trials on Information reports
-
Duke UniversityNorthern Piedmont Carolina Community Care Partners; North Carolina Division...CompletedCoronary Artery Disease | Hypertension | Diabetes | Asthma | Congestive Heart FailureUnited States
-
Phedra DoddsSwansea University; The Health FoundationCompletedElectronic Linkage for Inflammatory Bowel Disease to Deliver Joint Access to Health Reports (ELIJAH)Inflammatory Bowel DiseasesUnited Kingdom
-
University of AlbertaAlberta Innovates Health Solutions; Institute of Health Economics, CanadaRecruitingCritical Illness | Acute Kidney FailureCanada
-
University of AlbertaAlberta Innovates Health SolutionsRecruitingAcute Renal InjuryCanada
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI)CompletedLung Diseases | AsthmaUnited States
-
University Hospital, MontpellierInserm U1061 : NeuropsychiatryCompleted
-
Roswell Park Cancer InstituteActive, not recruitingMedication AdherenceUnited States
-
Avera McKennan Hospital & University Health CenterCellworks Group Inc.Recruiting
-
Mathematica Policy Research, Inc.Centers for Medicare and Medicaid ServicesCompletedMedicare Expenditures, Quality of CareUnited States
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)Active, not recruiting